HLA-DOB: A Potential Drug Target and Biomarker (G3112)

Target Name: HLA-DOB

NCBI ID: G3112

HLA-DOB

HLA-DOB: A Potential Drug Target and Biomarker

HLA-DOB (human leukocyte antigen DOB) is a protein that is expressed in the major histocompatibility complex (MHC) class I molecules. MHC class I molecules are a type of immune receptor that play a crucial role in the immune response. They are expressed in most tissues and cells of the body and are involved in the presentation of antigens from the immune system to the T-cells. HLA-DOB is one of the proteins that is expressed in MHC class I molecules.

HLA-DOB is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. HLA-DOB is able to interact with MHC class II molecules, which are also expressed in most tissues and cells of the body. This interaction between HLA-DOB and MHC class II molecules is important for the presentation of antigens to the T-cells.

HLA-DOB is also involved in the regulation of the immune response. For example, HLA-DOB has been shown to play a role in the regulation of the cytotoxic T-cell death, which is a natural mechanism that helps to eliminate infected or damaged cells.

Drug Targeting

HLA-DOB has been identified as a potential drug target for the treatment of various diseases. One of the main reasons for this is the fact that HLA-DOB is involved in many different processes in the body, and alterations in its expression levels can have a significant impact on the health of the body.

One of the main targets for HLA-DOB is the regulation of apoptosis (programmed cell death). Apoptosis is a natural mechanism that helps to eliminate infected or damaged cells from the body. However, HLA-DOB has been shown to play a role in the regulation of apoptosis, and alterations in its expression levels have been linked to an increased risk of certain diseases.

For example, studies have shown that HLA-DOB plays a role in the regulation of apoptosis in cancer cells. In these cells, HLA-DOB is expressed at higher levels than in normal cells, and it has been shown to promote the survival of cancer cells. This may be because HLA-DOB is involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer.

Another potential target for HLA-DOB is the regulation of inflammation. HLA-DOB is involved in the regulation of the immune response, and alterations in its expression levels have been linked to an increased risk of certain inflammatory diseases.

Biomarker

HLA-DOB is also a potential biomarker for certain diseases. For example, studies have shown that HLA-DOB is expressed at higher levels in individuals with certain autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. This may be because HLA-DOB is involved in the regulation of the immune response, and alterations in its expression levels may be a sign of an underlying immune disorder.

Conclusion

HLA-DOB is a protein that is expressed in MHC class I molecules and is involved in many different processes in the body. Its expression levels have been linked to a number of different diseases, including cancer and autoimmune disorders. As a result, HLA-DOB is a potential drug target and biomarker for the treatment of these diseases. Further research is needed to fully understand the role of HLA-DOB in the immune response and the regulation of disease.

Protein Name: Major Histocompatibility Complex, Class II, DO Beta

Functions: Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells. Modifies peptide exchange activity of HLA-DM

The "HLA-DOB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DOB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets